111822-66-3

Basic information

• Product Name: Propanamide, 3-[[2-hydroxy-3-[2-(methylsulfonyl)phenoxy]propyl](phenylmethyl)amino]- N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-
• CAS NO: 111822-66-3
• Molecular Formula: C31H36N4O6S
• Molecular Weight: 592.716
• Mol File: 111822-66-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Propanamide, 3-[[2-hydroxy-3-[2-(methylsulfonyl)phenoxy]propyl](phenylmethyl)amino]- N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Propanamide, 3-[[2-hydroxy-3-[2-(methylsulfonyl)phenoxy]propyl](phenylmethyl)amino]- N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-(111822-66-3)
• EPA Substance Registry System: Propanamide, 3-[[2-hydroxy-3-[2-(methylsulfonyl)phenoxy]propyl](phenylmethyl)amino]- N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-(111822-66-3)

Safety Data

• Hazardous Substances Data: 111822-66-3(Hazardous Substances Data)

Upstream product

• 36725-28-7 6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone 
• 111794-34-4 6-<4-(3-bromopropionamido)phenyl>-5-methyl-4,5-dihydro-3(2H)-pyridazinone 
• 27489-33-4 2-hydroxyphenyl methyl sulfone 
• 58048-49-0 1-<2-(methylsulfonyl)phenoxy>-2,3-epoxypropane 
• 111794-37-7 6-<4-<3-(benzylamino)propionamido>phenyl>-5-methyl-4,5-dihydro-3(2H)-pyridazinone hydrobromide 

Downstream Products

• 111794-58-2 3-[2-Hydroxy-3-(2-methanesulfonyl-phenoxy)-propylamino]-N-[4-(4-methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-propionamide 

Relevant articles and documents

Design and synthesis of a series of combined vasodilator/β-adrenoceptor antagonists based on 6-arylpyridazinones

A series of new 6-[4-[[(aryloxy)acyl]amino]phenyl]-4,5-dihydropyridazinones have been synthesized and evaluated as combined vasodilator/β-adrenoceptor antagonists and potential antihypertensive agents. Many of the early compounds displayed an unacceptably high level of intrinsic sympathomimetic activity (ISA) and a relatively short duration of action. Disubstitution in the 2,3-positions or in the 4-position of the aryloxy ring gave compounds with low ISA levels and, in some instances, improved duration of action. All of the compounds were vasodilators, but the 5-methylpyridazinone derivatives showed consistently greater antihypertensive activity than their 5-H lower homologues. Further detailed pharmacological investigations led to the selection of 6-[4-[3-[[2-hydroxy-3-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]propyl]amino ]propionamido]phenyl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone (4t) (SK&F 95018) as a development candidate.